Law360, New York (June 15, 2012, 7:43 PM ET) -- A Canadian appeals panel on Friday upheld the certification of a class of consumers who claim Wyeth Canada Inc.'s hormone drug Premarin causes breast cancer, clearing the way for the case to proceed to trial.
Wyeth Canada, part of Pfizer Inc., had sought to have the certification overturned, arguing that the lower-court judge who ordered it had ignored evidence disproving a link between Premarin and cancer, set an unmanageable class period and allowed a claim based on the Business Practices and Consumer Protection Act that was...
Wyeth Can't Kick Class Cert. In Canadian Suit Over Premarin
To view the full article, take a free trial now.
